Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase.
D000230:Adenocarcinoma / Q000503:physiopathology; D000818:Animals; D001081:Apyrase / Q000494:pharmacology*; D002460:Cell Line; D003110:Colonic Neoplasms / Q000503:physiopathology; D005910:Glioma / Q000503:physiopathology; D006629:Hirudins / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008175:Lung Neoplasms / Q000503:physiopathology; D008545:Melanoma / Q000503:physiopathology; D008654:Mesothelioma / Q000503:physiopathology; D051379:Mice; D009369:Neoplasms / Q000503:physiopathology*; D009374:Neoplasms, Experimental / Q000503:physiopathology; D009447:Neuroblastoma / Q000503:physiopathology; D010740:Phospholipases / Q000494:pharmacology*; D010744:Phosphoric Monoester Hydrolases / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects
D006629:Hirudins; D010740:Phospholipases; D010744:Phosphoric Monoester Hydrolases; D001081:Apyrase